Clinical stage oncology firm Oxford BioTherapeutics has signed a deal with the open-access biologics technology platform company WuXi Biologics, in a deal worth more than $450 million.
The alliance has come as part of an effort to develop and commercialise five novel bispecific antibodies as treatments for several different cancers, through the use of WuXi Biologics WuXiBody Platform.